Recipharm Holdings Limited’s £505 Million Recommended Cash Offer For Consort Medical plc


Ashurst is advising Lazard & Co., Limited in relation to the £505 million cash offer for Consort Medical plc by Recipharm Holdings Limited, a wholly owned subsidiary of Recipharm AB.

Recipharm AB is a company incorporated in Sweden, whose shares are listed on Nasdaq Stockholm. The Recipharm group is a leading contract development and manufacturing organisation (“CDMO”) in the pharmaceutical industry, offering manufacturing services for pharmaceuticals in various dosage forms, production of clinical trial material and active pharmaceutical ingredient, and pharmaceutical product development.

Consort Medical plc is a leading, global, single source pharma services drug and delivery device company. The transaction forms part of Recipharm’s growth plans to become a leading global CDMO.

Lazard is acting as financial adviser to Recipharm in relation to the offer.

The Ashurst team is being led by partners Karen Davies (Picture) and Tim Rennie, assisted by senior associate Darren Phelan and associates Demi Pham and Colin Bugler.

Involved fees earner: Colin Bugler – Ashurst; Karen Davies – Ashurst; Demi Pham – Ashurst; Darren Phelan – Ashurst; Tim Rennie – Ashurst;

Law Firms: Ashurst;

Clients: Lazard;